218 related articles for article (PubMed ID: 31217827)
21. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
22. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
23.
Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
[TBL] [Abstract][Full Text] [Related]
24. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
25. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.
Piras LA; Riccardo F; Iussich S; Maniscalco L; Gattino F; Martano M; Morello E; Lorda Mayayo S; Rolih V; Garavaglia F; De Maria R; Lardone E; Collivignarelli F; Mignacca D; Giacobino D; Ferrone S; Cavallo F; Buracco P
Vet Comp Oncol; 2017 Sep; 15(3):996-1013. PubMed ID: 27146852
[TBL] [Abstract][Full Text] [Related]
26. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
[TBL] [Abstract][Full Text] [Related]
27. MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.
Lopez CM; Yu PY; Zhang X; Yilmaz AS; London CA; Fenger JM
PLoS One; 2018; 13(1):e0190086. PubMed ID: 29293555
[TBL] [Abstract][Full Text] [Related]
28. Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4.
Egami Y; Narushima Y; Ohshima M; Yoshida A; Yoneta N; Masaki Y; Itoh K
J Biochem; 2018 Jan; 163(1):61-68. PubMed ID: 29036679
[TBL] [Abstract][Full Text] [Related]
29. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance.
Shahi MH; York D; Gandour-Edwards R; Withers SS; Holt R; Rebhun RB
PLoS One; 2015; 10(6):e0131006. PubMed ID: 26110620
[TBL] [Abstract][Full Text] [Related]
30. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA.
Riccardo F; Iussich S; Maniscalco L; Lorda Mayayo S; La Rosa G; Arigoni M; De Maria R; Gattino F; Lanzardo S; Lardone E; Martano M; Morello E; Prestigio S; Fiore A; Quaglino E; Zabarino S; Ferrone S; Buracco P; Cavallo F
Clin Cancer Res; 2014 Jul; 20(14):3753-62. PubMed ID: 24874834
[TBL] [Abstract][Full Text] [Related]
31. High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer.
Hsu NC; Nien PY; Yokoyama KK; Chu PY; Hou MF
Biochem Biophys Res Commun; 2013 Nov; 441(2):514-8. PubMed ID: 24177010
[TBL] [Abstract][Full Text] [Related]
32. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
[TBL] [Abstract][Full Text] [Related]
33. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.
Schiffer D; Mellai M; Boldorini R; Bisogno I; Grifoni S; Corona C; Bertero L; Cassoni P; Casalone C; Annovazzi L
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213051
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
[TBL] [Abstract][Full Text] [Related]
35. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
Grossauer A; Uranowska K; Kitzwögerer M; Mostegel M; Breiteneder H; Hafner C
Oncol Lett; 2023 Sep; 26(3):382. PubMed ID: 37559576
[TBL] [Abstract][Full Text] [Related]
37. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen.
Nounamo B; Jousheghany F; Siegel ER; Post SR; Kelly T; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768830
[TBL] [Abstract][Full Text] [Related]
38. Association between absolute tumor burden and serum bone-specific alkaline phosphatase in canine appendicular osteosarcoma.
Sternberg RA; Pondenis HC; Yang X; Mitchell MA; O'Brien RT; Garrett LD; Helferich WG; Hoffmann WE; Fan TM
J Vet Intern Med; 2013; 27(4):955-63. PubMed ID: 23734720
[TBL] [Abstract][Full Text] [Related]
39. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.
Fenger JM; London CA; Kisseberth WC
ILAR J; 2014; 55(1):69-85. PubMed ID: 24936031
[TBL] [Abstract][Full Text] [Related]
40. Investigating CXCR4 expression in canine appendicular osteosarcoma.
Fan TM; Barger AM; Fredrickson RL; Fitzsimmons D; Garrett LD
J Vet Intern Med; 2008; 22(3):602-8. PubMed ID: 18466248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
